ReviewMolecular oncology2021
Cancer diagnostics based on plasma protein biomarkers: hard times but great expectations.
Review in Molecular oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 108 citations in OpenAlex.
- Using human proteomic and lipidomic to exploration drug target of bladder cancer.World journal of urology · 2026Article
- Early Cancer Detection: What's Going on and What's Next.MedComm · 2026Review
- Emerging liquid biopsy tools to analyse cancer biomarkers: electrochemical sensors and extracellular vesicle analysis.Biochemical Society transactions · 2026Review
- Digging into the Solubility Factor in Cancer Diagnosis: A Case of Soluble CD44 Protein.Biosensors · 2025Review
- A secreted signature discriminates indolent from aggressive prostate tumors.World journal of urology · 2025Article
- Multiplexed Quantification of First-Trimester Serum Biomarkers in Healthy Pregnancy.International journal of molecular sciences · 2025Article
- The Impact of Peroxiredoxin 3 on Molecular Testing, Diagnosis, and Prognosis in Human Pancreatic Ductal Adenocarcinoma.Cancers · 2025Article
- The growing field of liquid biopsy and its Snowball effect on reshaping cancer management.The journal of liquid biopsy · 2025Review
- Current Advancements in Serum Protein Biomarkers for Hepatitis B Virus-Associated Hepatocyte Remodeling and Hepatocellular Carcinoma.Immunity, inflammation and disease · 2025Review
- Plasma proteins mediate the effects of the gut microbiota on the development of head and neck cancer: a two-sample and mediated Mendelian randomized study.Discover oncology · 2025Article
- Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring.Scientific reports · 2025Article
- Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study.Scientific reports · 2025Article
- A Mem-dELISA platform for dual color and ultrasensitive digital detection of colocalized proteins on extracellular vesicles.Biosensors & bioelectronics · 2025Article
- Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review.Frontiers in oncology · 2025Review
- Review
- Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy-A Narrative Review.Journal of clinical medicine · 2024Review
- Diagnostics and Therapy for Malignant Tumors.Biomedicines · 2024Review
- Development of a Serum Metabolome-Based Test for Early-Stage Detection of Multiple Cancers.Cancer reports (Hoboken, N.J.) · 2024Article
- Absolute Quantitative Targeted Monitoring of Potential Plasma Protein Biomarkers: A Pilot Study on Healthy Individuals.Biomedicines · 2024Article
- Causal inference of the effect of plasma proteins on the incidence of oral cancer: two-sample Mendelian randomization.BMC oral health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer diagnostics based on the detection of protein biomarkers in blood has promising potential for early detection and continuous monitoring of disease. However, the currently available protein biomarkers and assay formats largely fail to live up to expectations, mainly due to insufficient diagnostic specificity. Here, we discuss what kinds of plasma proteins might prove useful as biomarkers of malignant processes in specific organs. We consider the need to search for biomarkers deep down in the lowest reaches of the proteome, below current detection levels. In this regard, we comment on the poor molecular detection sensitivity of current protein assays compared to nucleic acid detection reactions, and we discuss requirements for achieving detection of vanishingly small amounts of proteins, to ensure detection of early stages of malignant growth through liquid biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.